Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey

Table 3 Duration of treatment and attack frequency for each type of LTP

Type of LTP	No. of attacks (%)	No. of patients (%)	Duration of LTP, y^a			Attack frequency (attacks/year)^c
Type of LTP	No. of attacks (%)	No. of patients (%)	Mean (SD)	Median (IQR)	Total duration^b	Attack frequency (attacks/year)^c
C1-INH	121 (12.4)	15 (8.8)	3.4 (1.4)	3.1 (2.6–3.7)	51.5	2.3
C1-INH/androgens^d	9 (0.9)	4 (2.3)	4.6 (1.4)	4.6 (3.4–5.8)	18.6	0.5
C1-INH/androgens/tranexamic acid	4 (0.4)	2 (1.2)	3.3 (1.9)	3.3 (1.9–4.6)	6.5	0.6
C1-INH/tranexamic acid	24 (2.5)	2 (1.2)	3.8 (1.1)	3.8 (3.1–4.6)	7.7	3.1
Androgens	542 (55.7)	108 (63.2)	3.5 (1.9)	3.4 (2.2–5.0)	372.7	1.5
Androgens/tranexamic acid	41 (4.2)	9 (5.3)	5.0 (1.3)	4.5 (4.1–6.0)	44.8	0.9
Tranexamic acid	232 (23.8)	43 (25.1)	3.4 (1.8)	3.8 (1.6–4.6)	147.1	1.6
Overall	973	171	3.5 (1.8)	3.6 (2.2–4.8)	620.5	1.6
No LTP^e	1941	277	3.6 (1.8)	3.4 (2.1–5.0)	985.4	2.0

C1-INH C1-inhibitor, IQR interquartile range, LTP long-term prophylaxis
^aThe start date of LTP was imputed to the date of the first treated attack if the patient started LTP before the date of the first attack
^bThe sum of maximum treatment duration. Treatments received by patients were included even if they were not related to treated attacks
^cIcatibant-treated attacks that occurred with or without LTP
^dAndrogens include danazol, stanozolol, and oxandrolone
^eThe duration (follow-up time) of icatibant treatment for patients who never received LTP. Duration was computed from first attack date to extract date, death date, or discontinuation date, as applicable. Patients who reported attacks with and without LTP were excluded

ISSN: 1710-1492